A NOTCH3 pathogenic variant influences osteogenesis and can be targeted by antisense oligonucleotides in induced pluripotent stem cells
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0316644 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Ernesto Canalis und 4 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Orthopaedic Surgery, UConn Musculoskeletal Institute, UConn Health, Farmington, CT, United States of America. Hauptthemen laut MEDLINE: Receptor, Notch3, Induced Pluripotent Stem Cells, Osteogenesis, Oligonucleotides, Antisense. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Abstract (Originalsprache)
Lateral Meningocele Syndrome (LMS), a disorder associated with NOTCH3 pathogenic variants, presents with neurological, craniofacial and skeletal abnormalities. Mouse models of the disease exhibit osteopenia that is ameliorated by the administration of Notch3 antisense oligonucleotides (ASO) targeting either Notch3 or the Notch3 mutation. To determine the consequences of LMS pathogenic variants in human cells and whether they can be targeted by ASOs, induced pluripotent NCRM1 and NCRM5 stem (iPS) cells harboring a NOTCH3 6692-93insC insertion were created. Parental iPSCs, NOTCH3 6692-93insC and isogenic controls, free of chromosomal aberrations as determined by human CytoSNP850 array, were cultured under conditions of neural crest, mesenchymal and osteogenic cell differentiation. The expected cell phenotype was confirmed by surface markers and a decline in OCT3/4 and NANOG mRNA. NOTCH3 6692-93insC cells displayed enhanced expression of Notch target genes HES1 , HEY1 , 2 and L demonstrating a NOTCH3 gain-of-function. There was enhanced osteogenesis in NOTCH3 6692-93insC cells as evidenced by increased mineralized nodule formation and ALPL , BGLAP and BSP expression. ASOs targeting NOTCH3 decreased both NOTCH3 wild type and NOTCH3 6692-93insC mutant mRNA by 40% in mesenchymal and 90% in osteogenic cells. ASOs targeting the NOTCH3 insertion decreased NOTCH3 6692-93insC by 70–80% in mesenchymal cells and by 45–55% in osteogenic cells and NOTCH3 mRNA by 15–30% and 20–40%, respectively. In conclusion, a NOTCH3 pathogenic variant causes a modest increase in osteoblastogenesis in human iPS cells in vitro and NOTCH3 and NOTCH3 mutant specific ASOs downregulate NOTCH3 transcripts associated with LMS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departments of Orthopaedic Surgery, UConn Musculoskeletal Institute, UConn Health, Farmington, CT, United States of America.
- Departments of Medicine, UConn Musculoskeletal Institute, UConn Health, Farmington, CT, United States of America.
- UConn Musculoskeletal Institute, UConn Health, Farmington, CT, United States of America.
- Ionis Pharmaceuticals, Inc., Carlsbad, CA, United States of America.
ORCID-Profile: Ernesto Canalis, Michele Carrer
Förderung
- NIAMS NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Canalis, E., Yu, J., Schilling, L., Jafar-Nejad, P., & Carrer, M. (2025). A NOTCH3 pathogenic variant influences osteogenesis and can be targeted by antisense oligonucleotides in induced pluripotent stem cells. PLOS ONE. https://doi.org/10.1371/journal.pone.0316644
Vancouver
Canalis E, Yu J, Schilling L, Jafar-Nejad P, Carrer M. A NOTCH3 pathogenic variant influences osteogenesis and can be targeted by antisense oligonucleotides in induced pluripotent stem cells. PLOS ONE. 2025. doi:10.1371/journal.pone.0316644
BibTeX
@article{Canalis2025,
author = {Canalis, Ernesto and Yu, Jungeun and Schilling, Lauren and Jafar-Nejad, Paymaan and Carrer, Michele},
title = {A NOTCH3 pathogenic variant influences osteogenesis and can be targeted by antisense oligonucleotides in induced pluripotent stem cells},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0316644}
}
EUVIMED